Showing all 3 results
Darifenacin Prolonged Release Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Hydrophilic Matrix Prolonged-Release Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute physical stability of the controlled-release polymer.
Active Ingredient Strength Primary Clinical Function Darifenacin Hydrobromide USP/Ph.Eur.
(Equivalent to Darifenacin base)7.5 mg (PR) The Standard Titration & Geriatric Anchor: The definitive, highly efficacious starting and maintenance dose utilized for the vast majority of patients to control OAB symptoms with minimal side effects. Darifenacin Hydrobromide USP/Ph.Eur. 15 mg (PR) The Severe Refractory Macrodose: High-efficacy therapeutic payload utilized strictly for patients who require greater symptom relief and have demonstrated high tolerability to the 7.5 mg dose. Excipients Hypromellose (HPMC) / Dibasic Calcium Phosphate / Magnesium Stearate / Polyethylene Glycol / Titanium Dioxide / Premium Polymeric Film Hydrophilic PR Matrix / Diluent / Lubricant / Plasticizer / Opaque Film (Engineered specifically utilizing high-viscosity Hypromellose. Upon contact with gastrointestinal fluids, the tablet hydrates to form a thick, gelatinous outer layer that strictly controls the diffusion of the highly soluble hydrobromide salt over a 24-hour period) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic urological dispensing regimens).
Mirabegron Extended-Release Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Hydrophilic Matrix ER Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute physical stability of the extended-release polymers.
Active Ingredient Strength Primary Clinical Function Mirabegron Ph.Eur./USP 25 mg (ER) Initiation / Renal Standard: Base therapeutic unit for assessing patient tolerance and for use in patients with severe renal or hepatic impairment. Mirabegron Ph.Eur./USP 50 mg (ER) Global Urology Standard: High-efficacy adult maintenance therapy for maximum suppression of urge urinary incontinence and detrusor overactivity. Excipients Polyethylene Oxide / Hypromellose (HPMC) / Butylated Hydroxytoluene (BHT) / Magnesium Stearate / Premium Opadry Film Swellable ER Polymer / Hydrophilic Matrix Base / Antioxidant / Lubricant (Engineered specifically to form an impenetrable, slow-eroding gel matrix in the GI tract, strictly metering the release of the active ingredient over 24 hours) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic urology dispensing regimens).
Oxybutynin Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Polymeric Matrix Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE desiccant bottles to ensure the absolute chemical stability of the controlled-release hydrogel network.
Active Ingredient Strength Primary Clinical Function Oxybutynin Chloride USP/Ph.Eur. 5 mg (ER) Initiation Standard: Base once-daily titration unit for the gradual introduction of antimuscarinic therapy. Oxybutynin Chloride USP/Ph.Eur. 10 mg / 15 mg (ER) Global Clinical Standard: Advanced maintenance doses for severe, refractory Overactive Bladder and neurogenic detrusor overactivity. Excipients Hypromellose (HPMC) / Lactose Anhydrous / Macrogol (PEG) / Magnesium Stearate / Titanium Dioxide Hydrophilic Polymer Matrix / Diluent / Plasticizer / Premium Film-Coating (Engineered specifically to form a highly viscous external gel barrier upon swallowing, controlling the exact 24-hour drug diffusion rate) *Pack Sizes: Bottles of 30 or 10×10 Alu-Alu Blisters (Optimized specifically for strict, high-compliance 30-day chronic urology dispensing regimens).
